Oryzon Genomics has received new ‘decision to grant’ communications from the Canadian Intellectual Property Office and the Israel Patent Office. This is for its patents ‘Methods of treating behavior alterations’ for lead CNS candidate, vafidemstat, as a potential treatment to address aggression and social withdrawal. Once granted, these patents will remain in force until at least 2038 in Canada and Israel, excluding any potential patent term extensions (which have the potential to add additional years of protection).
Oryzon is currently preparing for a Phase III programme, which will evaluate vafidemstat for the treatment of aggression in patients with borderline personality disorder.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment